Publications by authors named "Kayvon Modjarrad"

Claim this Profile
I
Immunologic and biophysical features of the BNT162b2 JN.1 and KP.2 adapted COVID-19 vaccines.
Wei Chen, Kristin R Tompkins, Ian W Windsor, Lyndsey T Martinez, Minah Ramos, Kayvon Modjarrad

Nat Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitigating the surge of mpox in Africa: capacity building through public outreach, sample and case management training for healthcare workers and veterinarians.
Michael Onyebuchi Iroezindu, Abdulwasiu Bolaji Tiamiyu, Zahra Folasade Parker, Danielle Bartolanzo, Edward Abayomi Akinwale, Kayvon Modjarrad

Pan Afr Med J· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Production of Clinical-Grade SARS-CoV-2 Spike Ferritin Nanoparticle Protein Immunogen by Transient Transfection.
Agnes Hajduczki, William C Chang, Rafael De La Barrera, James F Wood, Wei-Hung Chen, Kayvon Modjarrad

Vaccines (Basel)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial.
Oyeniyi Diya, Juleen Gayed, Francine S Lowry, Hua Ma, Vishva Bangad, Kayvon Modjarrad

Infect Dis Ther· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old.
Oyeniyi Diya, Juleen Gayed, Francine S Lowry, Hua Ma, Vishva Bangad, Kayvon Modjarrad

Vaccine· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lassa virus in novel hosts: insights into the epidemiology of lassa virus infections in southern Nigeria.
Anise Nkenjop Happi, Olusola Akinola Ogunsanya, Akeemat Opeyemi Ayinla, Ayotunde Elijah Sijuwola, Femi Mudasiru Saibu, Kayvon Modjarrad

Emerg Microbes Infect· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a next-generation live-attenuated yellow fever vaccine produced in a Vero cell line in the USA: a phase 1 randomised, observer-blind, active-controlled, dose-ranging clinical trial.
Kayvon Modjarrad, Paul T Scott, Melanie McCauley, Brittany Ober-Shepherd, Erica Sondergaard

Lancet Infect Dis· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine.
Kayvon Modjarrad, Ye Che, Wei Chen, Huixian Wu, Carla I Cadima

NPJ Vaccines· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Next generation yellow fever vaccine induces an equivalent immune and transcriptomic profile to the current vaccine: observations from a phase I randomised clinical trial.
Anke Pagnon, Christophe Carre, Marion Aguirre, Emilie Chautard, Sophie Gimenez, Kayvon Modjarrad

EBioMedicine· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activity.
Elizabeth J Martinez, William C Chang, Wei-Hung Chen, Agnes Hajduczki, Paul V Thomas, Kayvon Modjarrad

iScience· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seroprevalence and risk factors for Lassa virus infection in South-West and North-Central Nigeria: a community-based cross-sectional study.
Abdulwasiu B Tiamiyu, Olutunde A Adegbite, Olivia Freides, Seth Frndak, Samirah Sani Mohammed, Kayvon Modjarrad

BMC Infect Dis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical, molecular, and drug resistance epidemiology of HIV in Jordan, 2019-2021: A national study.
Faris G Bakri, Heyam H Mukattash, Hiam Esmeiran, Glenna Schluck, Casey K Storme, Kayvon Modjarrad

Int J Infect Dis· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial.
Juleen Gayed, Vishva Bangad, Xia Xu, Federico Mensa, Mark Cutler, Kayvon Modjarrad

Vaccines (Basel)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial.
Brittany L Ober Shepherd, Paul T Scott, Jack N Hutter, Christine Lee, Melanie D McCauley, Kayvon Modjarrad

Lancet Microbe· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain.
Rajeshwer S Sankhala, Vincent Dussupt, Wei-Hung Chen, Hongjun Bai, Elizabeth J Martinez, Kayvon Modjarrad

Structure· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence of Zika Virus Reinfection by Genome Diversity and Antibody Response Analysis, Brazil.
Marcia da Costa Castilho, Ana Maria Bispo de Filippis, Lais Ceschini Machado, Thaise Yasmine Vasconcelos de Lima Calvanti, Morganna Costa Lima, Kayvon Modjarrad

Emerg Infect Dis· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zika purified inactivated virus (ZPIV) vaccine reduced vertical transmission in pregnant immunocompetent mice.
In-Jeong Kim, Michael P Tighe, Paula A Lanthier, Madeline J Clark, Rafael A De La Barrera, Kayvon Modjarrad

NPJ Vaccines· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protective efficacy of a Zika purified inactivated virus vaccine candidate during pregnancy in marmosets.
In-Jeong Kim, Olga Gonzalez, Michael P Tighe, Paula A Lanthier, Madeline J Clark, Kayvon Modjarrad

NPJ Vaccines· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of sexually transmitted infections among U.S. military service members in the setting of HIV pre-exposure prophylaxis use.
Jason M Blaylock, Evan C Ewers, Elizabeth J Bianchi, David B King, Rosemary O Casimier, Kayvon Modjarrad

PLoS One· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques.
Rajeshwer S Sankhala, Kerri G Lal, Jaime L Jensen, Vincent Dussupt, Letzibeth Mendez-Rivera, Kayvon Modjarrad

Nat Commun· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial.
Juleen Gayed, Oyeniyi Diya, Francine S Lowry, Xia Xu, Vishva Bangad, Kayvon Modjarrad

Vaccines (Basel)· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial.
Betty Mwesigwa, Katherine V Houser, Amelia R Hofstetter, Ana M Ortega-Villa, Prossy Naluyima, Kayvon Modjarrad

Lancet Infect Dis· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection and persistence of Zika virus in body fluids and associated factors: a prospective cohort study.
Guilherme Amaral Calvet, Edna Oliveira Kara, Camila Helena Aguiar Bôtto-Menezes, Marcia da Costa Castilho, Rafael Freitas de Oliveira Franca, Kayvon Modjarrad

Sci Rep· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Priming with Japanese encephalitis virus or yellow fever virus vaccination led to the recognition of multiple flaviviruses without boosting antibody responses induced by an inactivated Zika virus vaccine.
Yifan Li, Mélanie Merbah, Suzanne Wollen-Roberts, Bradley Beckman, Thembi Mdluli, Kayvon Modjarrad

EBioMedicine· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes.
Rajeshwer S Sankhala, Vincent Dussupt, Gina Donofrio, Gregory D Gromowski, Rafael A De La Barrera, Kayvon Modjarrad

Cell Rep· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis